Prot# CRAD001N2201: An Open-Label, Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date7/22/084/5/11

Funding

  • Novartis Pharmaceuticals Corporation (CRAD001N2201)